Clinical development of the COVID-19 vaccine candidate ChAdOx1 nCoV-19, a replication-deficient simian adenoviral vector expressing the full-length SARS-CoV-2 spike (S) protein was initiated in April 2020 following non-human primate studies using a single immunisation. Here, we compared the immunogenicity of one or two doses of ChAdOx1 nCoV-19 in both mice and pigs. Whilst a single dose induced antigen-specific antibody and T cells responses, a booster immunisation enhanced antibody responses, particularly in pigs, with a significant increase in SARS-CoV-2 neutralising titres.
All Keywords
【저자키워드】 Virology, Vaccines, 【초록키워드】 SARS-CoV-2, COVID-19 vaccine, antibody, Protein, mice, clinical, adenoviral vector, non-human primate, ChAdOx1 nCoV-19, booster, single dose, dose, titres, significant increase, antigen-specific antibody, responses, neutralising, initiated, expressing, full-length SARS-CoV-2, T cells responses, 【제목키워드】 COVID-19 vaccine, vaccination, ChAdOx1 nCoV-19,
【저자키워드】 Virology, Vaccines, 【초록키워드】 SARS-CoV-2, COVID-19 vaccine, antibody, Protein, mice, clinical, adenoviral vector, non-human primate, ChAdOx1 nCoV-19, booster, single dose, dose, titres, significant increase, antigen-specific antibody, responses, neutralising, initiated, expressing, full-length SARS-CoV-2, T cells responses, 【제목키워드】 COVID-19 vaccine, vaccination, ChAdOx1 nCoV-19,